Search - tctmd.com

Displaying 121 - 140 of 160

Sort: Relevancy | Date

Presentation

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Presenter: K.A. Fiedler

April 22, 2015

News Daily News

Study Suggests Routine Bridging Harmful for A-fib Patients Interrupting Anticoagulation

December 22, 2014

News Daily News

Vorapaxar podría Proteger frente a ACV Isquémicos Incidentales y Trombosis del Stent

Todd Neale

December 04, 2014

News Daily News

Vorapaxar May Protect Against Incident Ischemic Stroke, Stent Thrombosis

Todd Neale

December 04, 2014

Presentation TCT 2014

Reversal of Factor Xa Inhibition

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Lisa K. Jennings

September 15, 2014

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff

September 15, 2014

Presentation TCT 2014

PCI and Anticoagulation: Triple Therapy

Presenter: Jurrien M. Ten Berg

September 13, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

News Daily News

Meta-analysis: Bone Marrow Stem Cell Research Riddled with Discrepancies

L.A. McKeown

May 13, 2014

News Daily News

COURAGE Substudy: Anatomy Trumps Ischemia for Predicting Outcomes

January 15, 2014

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

News Daily News

SYNTAX: Stent Thrombosis Has Greater Impact on Mortality Than Graft Occlusion

Leah Lawrence

October 25, 2013

Presentation

Comparison of Dual vs. Triple Antiplatelet Therapy After DES According to Stent Length

Presenter: S-W Lee

September 26, 2013

News Conference News ESC 2013

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

Caitlin E. Cox

September 01, 2013

News Daily News

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

August 30, 2013

Advertisement

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Study Suggests Routine Bridging Harmful for A-fib Patients Interrupting Anticoagulation

Vorapaxar podría Proteger frente a ACV Isquémicos Incidentales y Trombosis del Stent

Vorapaxar May Protect Against Incident Ischemic Stroke, Stent Thrombosis

Reversal of Factor Xa Inhibition

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

PCI and Anticoagulation: Triple Therapy

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Meta-analysis: Bone Marrow Stem Cell Research Riddled with Discrepancies

COURAGE Substudy: Anatomy Trumps Ischemia for Predicting Outcomes

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

SYNTAX: Stent Thrombosis Has Greater Impact on Mortality Than Graft Occlusion

Comparison of Dual vs. Triple Antiplatelet Therapy After DES According to Stent Length

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content